# BostonGene Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bostongene

- Industry: Healthcare IT
- Headquarters: Waltham, US
- Website: www.bostongene.com
- Total disclosed funding: $150M
- Latest round: Series B (Apr 6, 2022)
- Investors on record: 3

## About

BostonGene Corporation focuses on precision medicine solutions utilizing its proprietary Multiomic AI Platform to analyze complex data types, thereby supporting oncology treatments and enhancing patient outcomes.Founded in 2015 in Waltham, US, BostonGene Corporation operates in the field of precision medicine, specializing in oncology. The company has conducted 2 deals, with its most recent deal occurring on April 6, 2022, during which it raised USD 150 mn in Series B funding led by NEC Corporation, alongside contributions from Impact Investment Capital and Japan Industrial Partners. Andrew Feinberg serves as both the CEO and Founder of the company.BostonGene Corporation specializes in delivering advanced precision medicine solutions through its proprietary Multiomic AI Platform. This platform integrates various data types, including genomic, transcriptomic, and proteomic information, to facilitate the identification of biomarkers, enhance clinical trial designs, and support drug development processes. Core offerings encompass the Tumor Portrait™ test, Liquid Biopsy test, and Immune System Profiling, all aimed at addressing unmet medical needs in oncology and improving patient outcomes. The company serves a diverse clientele, including biopharmaceutical companies, clinical research organizations, and healthcare providers across various geographical markets, including North America, Europe, and Asia.BostonGene generates revenue through partnerships and collaborations with leading biopharmaceutical companies, as well as direct service offerings to healthcare institutions. Transactions typically occur via contractual agreements for the provision of its suite of diagnostic and profiling services, including its flagship Tumor Portrait™ test. The company engages primarily in B2B interactions, delivering its services to clinical partners who utilize the data for enhancing patient treatment strategies. Revenue streams may also include subscriptions for ongoing access to its Multiomic AI Platform, allowing clients to integrate advanced analytics into their research and clinical workflows. Specific pricing structures for products and services are tailored to client needs and project scopes, ensuring customization to meet the demands of various stakeholders in the oncology landscape.In April 2022, BostonGene Corporation raised USD 150 mn in Series B funding, led by NEC Corporation, to drive research and development, clinical expansion, and international availability of its Tumor Portrait™ tests. The company is focused on launching new products and enhancing its offerings to meet the increasing demand in the oncology space. Planned expansions include new markets across Europe and Asia by 2024, leveraging the recent funding to achieve these initiatives.

## Funding rounds

- Series B, Apr 6, 2022, $150M — NEC, Japan Industrial Partners, Impact Investment Capital

## Investors

- NEC — Series B
- Japan Industrial Partners (https://capitalatlas.ai/funds/japan-industrial-partners) — Series B
- Impact Investment Capital — Series B